Swiss National Bank Has $5.25 Million Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Swiss National Bank raised its position in Certara, Inc. (NASDAQ:CERTGet Rating) by 17.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 244,500 shares of the company’s stock after buying an additional 36,800 shares during the quarter. Swiss National Bank’s holdings in Certara were worth $5,247,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. EQT Fund Management S.a r.l. acquired a new position in Certara in the 2nd quarter valued at $771,679,000. Vanguard Group Inc. grew its holdings in Certara by 5.4% in the 1st quarter. Vanguard Group Inc. now owns 9,813,616 shares of the company’s stock valued at $210,797,000 after buying an additional 503,548 shares in the last quarter. BlackRock Inc. grew its holdings in Certara by 1.1% in the 1st quarter. BlackRock Inc. now owns 6,540,553 shares of the company’s stock valued at $140,491,000 after buying an additional 74,266 shares in the last quarter. Riverbridge Partners LLC grew its holdings in Certara by 0.5% in the 2nd quarter. Riverbridge Partners LLC now owns 4,528,385 shares of the company’s stock valued at $97,179,000 after buying an additional 22,636 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Certara by 9.7% during the 1st quarter. JPMorgan Chase & Co. now owns 3,910,996 shares of the company’s stock worth $84,008,000 after purchasing an additional 346,460 shares in the last quarter. 77.42% of the stock is owned by institutional investors and hedge funds.

Certara Price Performance

Shares of CERT stock opened at $16.49 on Friday. The company has a quick ratio of 3.99, a current ratio of 3.99 and a debt-to-equity ratio of 0.28. Certara, Inc. has a twelve month low of $10.60 and a twelve month high of $29.99. The company has a market cap of $2.63 billion, a P/E ratio of -549.67, a P/E/G ratio of 1.10 and a beta of 1.09. The business has a fifty day simple moving average of $13.19 and a 200 day simple moving average of $17.29.

Analysts Set New Price Targets

CERT has been the topic of several analyst reports. Piper Sandler reduced their target price on Certara from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, August 10th. Credit Suisse Group reduced their target price on Certara from $22.00 to $20.00 and set an “outperform” rating on the stock in a report on Monday, November 14th. SVB Leerink reduced their target price on Certara from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, August 10th. Berenberg Bank initiated coverage on Certara in a report on Thursday, September 8th. They set a “buy” rating and a $23.00 target price on the stock. Finally, Morgan Stanley reduced their target price on Certara from $24.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 24th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.14.

Insider Buying and Selling

In related news, Director Matthew M. Walsh sold 12,059 shares of the company’s stock in a transaction on Monday, November 14th. The stock was sold at an average price of $14.74, for a total transaction of $177,749.66. Following the completion of the sale, the director now directly owns 167,901 shares in the company, valued at approximately $2,474,860.74. The sale was disclosed in a filing with the SEC, which is available through this link. In other Certara news, Director Matthew M. Walsh sold 12,059 shares of the stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $14.74, for a total value of $177,749.66. Following the completion of the transaction, the director now directly owns 167,901 shares in the company, valued at $2,474,860.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Leif E. Pedersen sold 51,223 shares of the stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $15.55, for a total value of $796,517.65. Following the completion of the transaction, the insider now owns 175,500 shares of the company’s stock, valued at $2,729,025. The disclosure for this sale can be found here. 4.02% of the stock is owned by corporate insiders.

About Certara

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.

Featured Articles

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERTGet Rating).

Institutional Ownership by Quarter for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.